Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) Marketable Securities: HK$41.72 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03378 Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
11 GF Score
Price HK$28.60
! 1 Warning Sign
View Full Analysis

What is Hanx Biopharmaceuticals (Wuhan) Co Marketable Securities?

Hanx Biopharmaceuticals (Wuhan) Co HKSE:03378 +4.38% 11 Marketable Securities is HK$41.72 Mil as of Dec. 2025. GuruFocus rates HKSE:03378 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Hanx Biopharmaceuticals (Wuhan) Co's Marketable Securities for the quarter that ended in Dec. 2025 was HK$41.72 Mil.

Hanx Biopharmaceuticals (Wuhan) Co's annual Marketable Securities declined from Dec. 2023 (HK$46.33 Mil) to Dec. 2024 (HK$13.52 Mil) but then increased from Dec. 2024 (HK$13.52 Mil) to Dec. 2025 (HK$41.72 Mil).

Hanx Biopharmaceuticals (Wuhan) Co  (HKSE:03378) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Hanx Biopharmaceuticals (Wuhan) Co Marketable Securities Related Terms

Hanx Biopharmaceuticals (Wuhan) Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Hanx Biopharmaceuticals (Wuhan) Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hanx Biopharmaceuticals (Wuhan) Co Marketable Securities Chart

Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend Dec23 Dec24 Dec25
Marketable Securities
46.33 13.52 41.72

Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23 Dec24 Dec25 Jun26
Marketable Securities 46.33 13.52 41.72 50.88
HKSE:03378
11GF Score
Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hanx Biopharmaceuticals (Wuhan) Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of HK$41.72 Mil mean?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a Marketable Securities of HK$41.72 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors.
Is Hanx Biopharmaceuticals (Wuhan) Co's Marketable Securities too high?
Hanx Biopharmaceuticals (Wuhan) Co's current Marketable Securities is HK$41.72 Mil. Overall, Hanx Biopharmaceuticals (Wuhan) Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hanx Biopharmaceuticals (Wuhan) Co's Marketable Securities compare to VRTX and REGN?
Hanx Biopharmaceuticals (Wuhan) Co's Marketable Securities of HK$41.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. Hanx Biopharmaceuticals (Wuhan) Co's current Marketable Securities is HK$41.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanx Biopharmaceuticals (Wuhan) Co stock overvalued right now?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a current Marketable Securities of HK$41.72 Mil. The current Marketable Securities is HK$41.72 Mil. Hanx Biopharmaceuticals (Wuhan) Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378), the current Marketable Securities is HK$41.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hanx Biopharmaceuticals (Wuhan) Co Business Description

Address No. 1 Jiufeng 1st Road, Building A8, Phase II, Bio-Innovation Park, East Lake New Technology Development Zone, Hubei, Wuhan, CHN
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score

Get the complete analysis for HKSE:03378

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$28.60
Price